$LBRX

LB PHARMACEUTICALS INC (LBRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer NEW YORK, September 15, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commerciali

LB Pharmaceuticals (LBRX) appointed Joseph Miller as CFO, bringing 20+ years of biotech financial experience. CEO Heather Turner highlighted upcoming NOVA-2 trial results and potential schizophrenia drug launch. Shares traded 0.75% lower at $49.11 in pre-market.

LB PHARMACEUTICALS INC (LBRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer NEW YORK, September 3, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing hig

Wall Street analysts updated price targets and ratings for several companies. Baird cut Chipotle's (CMG) target to $40 and downgraded it to Neutral. HC Wainwright raised LB Pharmaceuticals' (LBRX) target to $60. BTIG increased AtriCure's (ATRC) target to $55. Baird also raised Analog Devices' (ADI) target to $675 and upgraded Darden Restaurants' (DRI) target to $250. Other notable changes include updates for Black Rock Coffee Bar (BRCB), Marti Technologies (MRT), Alkami Technology (ALKT), Chenie

LB Pharmaceuticals (LBRX) reported Q2 2026 results and updated its LB-102 schizophrenia program. The company expects earlier topline Phase 3 NOVA-2 data in 1H 2027 and a pre-NDA FDA meeting in 2H 2027. It is also advancing bipolar I depression (Q1 2028) and planning adjunctive MDD (1H 2029). R&D was $44.1M, net loss $51.6M, and it raised $150M.

LB PHARMACEUTICALS INC (LBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

LB Pharmaceuticals Inc (Nasdaq: LBRX) said it entered a securities purchase agreement for a private placement selling 3,577,560 shares of common stock and pre-funded warrants for up to 715,513 shares. Price was $34.94 per share and $34.9399 per pre-funded warrant. Gross proceeds are expected at about $150 million, before expenses, closing around July 30, 2026. Net proceeds will fund LB-102 pipeline expansion and working capital.

LB PHARMACEUTICALS INC (LBRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 LB Pharmaceuticals Announces $150 Million Private Placement NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) – LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact ther

Biotech shares hit 52-week highs on July 28, 2026. Incyte (INCY) rose over 9% to $132.58 after Q2 revenue of $1.67B, up 38% year over year, and raised full-year net sales guidance to $5.13B-$5.26B. Pulse Biosciences (PLSE) gained over 8% to $36.29. Other climbers included Shoulder Innovations (SI), Bioventus (BVS), and LB Pharmaceuticals (LBRX).